Piper Sandler initiated coverage of Upstream Bio (UPB) with an Overweight rating and $75 price target The analyst believes Upstream’s verekitug has a differentiated mechanism of action that targets the TSLP receptor versus ligand. Accordingly, the TSLP ligand has been de-risked by Tezspire’s 2021 approval in severe asthma, which represents a rapidly growing biologic market opportunity of $7.5B, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue